Will Sanofi, Genzyme chiefs talk deal at JPMorgan?

Could it be time to talk in the long-running saga of Sanofi-Aventis' ($SNY) $18.5 billion bid for Genzyme ($GENZ)? CEOs Chris Viehbacher (photo) and Henri Termeer (photo) will have the chance when they give back-to-back presentation's at next week's JPMorgan Healthcare Conference. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.